A phase IIb, multicenter, randomized, double-blind, parallel group, placebo-controlled efficacy and safety study of adjunctive AZD6765 in subjects with major depressive disorder (MDD) with at least moderate symptomatology and a history of poor response to antidepressants
Rimal B. Bera, MD
UC Irvine Medical Center
The purpose of this research study is to determine whether AZD6765, an investigational drug, has an effect on depression when taken together with current prescribed depression medication. AZD6765 is being developed for individuals with symptoms of depression and who have responded poorly to currently available antidepressants.
You are eligible to participate in this study if you are between 18 and 65 years of age and have been diagnosed with Major Depressive Disorder and have not responded to treatment with two or more antidepressants. You must also be currently taking an FDA-approved antidepressant for at least six weeks.
The length of participation can last up to 13 weeks.
You may or may not experience any direct health benefits during or after completing this study. The study drug may help your depression but it may not.
Total compensation for completing the study is up to $680.00.
Dr. Rimal B. Bera’s Research Team, Department of Psychiatry and Human Behavior